We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
-21.9%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.8B
AUM Growth
-$63.5M
(-3.4%)
Cap. Flow
+$448M
Cap. Flow
% of AUM
24.92%
Top 10 Holdings %
Top 10 Hldgs %
55.9%
Holding
105
New
11
Increased
30
Reduced
27
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$58.4M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
+$57.5M |
| 3 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$30.2M |
| 4 |
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
|
+$18.2M |
| 5 |
MASI
Masimo
MASI
|
+$17.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASRT
Assertio
ASRT
|
+$25.1M |
| 2 |
ALR
Alere Inc
ALR
|
+$23.9M |
| 3 |
Heron Therapeutics
HRTX
|
+$17.8M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$12.8M |
| 5 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$9.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.28% |
| 2 | Technology | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares Russell 2000 ETF
IWM
$81.8B
| $437M | 24.3% |
4,000,000
+2,250,000
| +129% | +$267M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $132M | 7.35% |
6,665,391
+1,849,584
| +38% | +$58.4M |
|
|
NVRO
3
DELISTED
NEVRO CORP.
NVRO
| $74.6M | 4.15% |
1,607,085
+1,187,526
| +283% | +$57.5M |
|
|
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
| $71.7M | 3.99% |
4,394,464
-580,720
| -12% | -$12.8M |
|
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $62.3M | 3.46% |
1,000,000
+145,000
| +17% | +$11.4M |
|
6
Travere Therapeutics
TVTX
$5.18B
| $52.9M | 2.94% |
2,609,790
+446,862
| +21% | +$13.2M |
|
|
PGNX
7
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $51.2M | 2.85% |
8,951,169
| – | – |
|
8
Emergent Biosolutions
EBS
$391M
| $46.2M | 2.57% |
1,621,832
-138,687
| -8% | -$4.57M |
|
|
9
Heron Therapeutics
HRTX
$90.4M
| $45.4M | 2.53% |
1,862,001
-534,680
| -22% | -$17.8M |
|
10
AngioDynamics
ANGO
$564M
| $31.6M | 1.76% |
2,398,527
| – | – |
|
|
AEGR
11
DELISTED
Aegerion Pharmaceuticals
AEGR
| $31.6M | 1.76% |
2,320,366
-532,212
| -19% | -$9.48M |
|
|
LJPC
12
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $30.4M | 1.69% |
1,095,373
+335,903
| +44% | +$10.6M |
|
|
BDSI
13
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $26.4M | 1.47% |
4,744,060
+1,200,000
| +34% | +$8.86M |
|
|
SCTL
14
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $24.8M | 1.38% |
2,296,996
+720,907
| +46% | +$9.19M |
|
|
NVDQ
15
DELISTED
Novadaq Technologies Inc.
NVDQ
| $19.9M | 1.11% |
1,908,648
+1,384,785
| +264% | +$16.4M |
|
|
RXDX
16
DELISTED
Ignyta, Inc.
RXDX
| $19.8M | 1.1% |
2,256,546
| – | – |
|
|
DVAX
17
DELISTED
Dynavax Technologies
DVAX
| $19.4M | 1.08% |
789,710
+23,700
| +3% | +$671K |
|
|
PTX
18
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
| $19.2M | 1.07% |
609,083
+101,490
| +20% | +$4.86M |
|
|
CSII
19
DELISTED
Cardiovascular Systems, Inc.
CSII
| $19M | 1.06% |
+1,200,000
| New | +$30.2M |
|
|
ADXS
20
DELISTED
Advaxis Inc
ADXS
| $17.8M | 0.99% |
115,789
+19,116
| +20% | +$4.62M |
|
|
ACGN
21
DELISTED
Aceragen Inc
ACGN
| $17.5M | 0.97% |
38,376
-3,312
| -8% | -$1.46M |
|
|
CORI
22
DELISTED
Corium International, Inc.
CORI
| $16.9M | 0.94% |
1,802,092
+297,330
| +20% | +$3.56M |
|
|
MASI
23
DELISTED
Masimo
MASI
| $16.3M | 0.9% |
+421,728
| New | +$17.2M |
|
|
SPNE
24
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $16.2M | 0.9% |
+1,000,007
| New | +$16.3M |
|
25
Zevra Therapeutics
ZVRA
$738M
| $15.5M | 0.86% |
49,987
-1,751
| -3% | -$536K |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q3 2015 Portfolio in Review
As of Q3 2015, Broadfin Capital held 105 positions worth $1.8B, down 3.4% from $1.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Broadfin Capital deployed $448M of net new capital in Q3 2015, opening 11 new positions and adding to 30 existing holdings. Its largest new stake was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 76% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Heron Therapeutics, an estimated $17.8M trimmed.
- Broadfin Capital's largest Q3 2015 buy was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.
- Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015, an estimated $58.4M increase.
- Broadfin Capital's biggest Q3 2015 reduction was Heron Therapeutics, cutting an estimated $17.8M.
- Broadfin Capital fully exited Assertio in Q3 2015, selling an estimated $25.1M.
- Broadfin Capital's ten largest holdings make up 56% of its $1.8B portfolio in Q3 2015.
- Broadfin Capital opened 11 new positions and closed 15 in Q3 2015.
- Broadfin Capital's portfolio value fell 3.4% quarter-over-quarter to $1.8B.
Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.